{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:49:54Z","timestamp":1792633794051,"version":"4.5.0"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T00:00:00Z","timestamp":1529539200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T00:00:00Z","timestamp":1529539200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["128608-RSGI-15-211-01-CPHPS"],"award-info":[{"award-number":["128608-RSGI-15-211-01-CPHPS"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["U54GM115677"],"award-info":[{"award-number":["U54GM115677"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s11864-018-0555-8","type":"journal-article","created":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T02:41:00Z","timestamp":1529548860000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":160,"title":["Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence"],"prefix":"10.1007","volume":"19","author":[{"given":"Thomas A.","family":"Ollila","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Olszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,21]]},"reference":[{"key":"555_CR1","unstructured":"Swerdlow SH, World Health Organization, International Agency for Research on Cancer. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th edition. ed. World Health Organization classification of tumours. Lyon: International Agency for Research on Cancer; 2017."},{"issue":"3","key":"555_CR2","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/ajh.23638","volume":"89","author":"JJ Castillo","year":"2014","unstructured":"Castillo JJ, Winer ES, Olszewski AJ. Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: an analysis of the Surveillance, Epidemiology and End Results database. Am J Hematol. 2014;89(3):310\u20134. \n                      https:\/\/doi.org\/10.1002\/ajh.23638\n                      \n                    .","journal-title":"Am J Hematol"},{"issue":"11","key":"555_CR3","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1002\/ajh.24169","volume":"90","author":"TC El-Galaly","year":"2015","unstructured":"El-Galaly TC, Villa D, Alzahrani M, Hansen JW, Sehn LH, Wilson D, et al. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET\/CT and rituximab era: a Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma. Am J Hematol. 2015;90(11):1041\u20136. \n                      https:\/\/doi.org\/10.1002\/ajh.24169\n                      \n                    .","journal-title":"Am J Hematol"},{"issue":"9","key":"555_CR4","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.3109\/10428194.2010.504872","volume":"51","author":"D Hui","year":"2010","unstructured":"Hui D, Proctor B, Donaldson J, Shenkier T, Hoskins P, Klasa R, et al. Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone. Leuk Lymphoma. 2010;51(9):1658\u201367. \n                      https:\/\/doi.org\/10.3109\/10428194.2010.504872.","journal-title":"Leuk Lymphoma"},{"issue":"18","key":"555_CR5","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","volume":"23","author":"P Feugier","year":"2005","unstructured":"Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23(18):4117\u201326. \n                      https:\/\/doi.org\/10.1200\/JCO.2005.09.131\n                      \n                    .","journal-title":"J Clin Oncol"},{"issue":"2","key":"555_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","volume":"9","author":"M Pfreundschuh","year":"2008","unstructured":"Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9(2):105\u201316. \n                      https:\/\/doi.org\/10.1016\/S1470-2045(08)70002-0\n                      \n                    .","journal-title":"Lancet Oncol"},{"issue":"9880","key":"555_CR7","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(13)60313-X","volume":"381","author":"D Cunningham","year":"2013","unstructured":"Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 2013;381(9880):1817\u201326. \n                      https:\/\/doi.org\/10.1016\/S0140-6736(13)60313-X\n                      \n                    .","journal-title":"Lancet"},{"issue":"2","key":"555_CR8","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1182\/blood-2017-07-793984","volume":"131","author":"T Lamy","year":"2018","unstructured":"Lamy T, Damaj G, Soubeyran P, Gyan E, Cartron G, Bouabdallah K, et al. R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. Blood. 2018;131(2):174\u201381. \n                      https:\/\/doi.org\/10.1182\/blood-2017-07-793984\n                      \n                    .","journal-title":"Blood"},{"issue":"6","key":"555_CR9","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","volume":"123","author":"Z Zhou","year":"2014","unstructured":"Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837\u201342. \n                      https:\/\/doi.org\/10.1182\/blood-2013-09-524108\n                      \n                    .","journal-title":"Blood"},{"issue":"8","key":"555_CR10","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.leukres.2014.04.009","volume":"38","author":"AJ Olszewski","year":"2014","unstructured":"Olszewski AJ, Winer ES, Castillo JJ. Improved survival with rituximab-based chemoimmunotherapy in older patients with extranodal diffuse large B-cell lymphoma. Leuk Res. 2014;38(8):866\u201373. \n                      https:\/\/doi.org\/10.1016\/j.leukres.2014.04.009\n                      \n                    .","journal-title":"Leuk Res"},{"issue":"4","key":"555_CR11","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1016\/S1470-2045(13)70568-0","volume":"15","author":"AJ Ferreri","year":"2014","unstructured":"Ferreri AJ. Risk of CNS dissemination in extranodal lymphomas. Lancet Oncol. 2014;15(4):e159\u201369. \n                      https:\/\/doi.org\/10.1016\/S1470-2045(13)70568-0\n                      \n                    .","journal-title":"Lancet Oncol"},{"issue":"8","key":"555_CR12","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1007\/s10552-015-0610-8","volume":"26","author":"AJ Olszewski","year":"2015","unstructured":"Olszewski AJ, Winer ES, Castillo JJ. Validation of clinical prognostic indices for diffuse large B-cell lymphoma in the National Cancer Data Base. Cancer Causes Control. 2015;26(8):1163\u201372. \n                      https:\/\/doi.org\/10.1007\/s10552-015-0610-8\n                      \n                    .","journal-title":"Cancer Causes Control"},{"issue":"6","key":"555_CR13","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1111\/bjh.14489","volume":"176","author":"C Montalban","year":"2017","unstructured":"Montalban C, Diaz-Lopez A, Dlouhy I, Rovira J, Lopez-Guillermo A, Alonso S, et al. Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of beta2-microglobulin yields a more accurate GELTAMO-IPI. Br J Haematol. 2017;176(6):918\u201328. \n                      https:\/\/doi.org\/10.1111\/bjh.14489\n                      \n                    .","journal-title":"Br J Haematol"},{"issue":"17","key":"555_CR14","doi-asserted-by":"publisher","first-page":"4166","DOI":"10.1002\/cncr.27381","volume":"118","author":"H Takahashi","year":"2012","unstructured":"Takahashi H, Tomita N, Yokoyama M, Tsunoda S, Yano T, Murayama K, et al. Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era. Cancer. 2012;118(17):4166\u201372. \n                      https:\/\/doi.org\/10.1002\/cncr.27381\n                      \n                    .","journal-title":"Cancer"},{"issue":"7","key":"555_CR15","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.3109\/10428194.2014.982636","volume":"56","author":"CS Lu","year":"2015","unstructured":"Lu CS, Chen JH, Huang TC, Wu YY, Chang PY, Dai MS, et al. Diffuse large B-cell lymphoma: sites of extranodal involvement are a stronger prognostic indicator than number of extranodal sites in the rituximab era. Leuk Lymphoma. 2015;56(7):2047\u201355. \n                      https:\/\/doi.org\/10.3109\/10428194.2014.982636\n                      \n                    .","journal-title":"Leuk Lymphoma"},{"issue":"6769","key":"555_CR16","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503\u201311. \n                      https:\/\/doi.org\/10.1038\/35000501\n                      \n                    .","journal-title":"Nature"},{"issue":"25","key":"555_CR17","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMoa012914","volume":"346","author":"A Rosenwald","year":"2002","unstructured":"Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937\u201347. \n                      https:\/\/doi.org\/10.1056\/NEJMoa012914\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"5","key":"555_CR18","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1182\/blood-2013-10-535021","volume":"124","author":"N Murawski","year":"2014","unstructured":"Murawski N, Held G, Ziepert M, Kempf B, Viardot A, Hanel M, et al. The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas. Blood. 2014;124(5):720\u20138. \n                      https:\/\/doi.org\/10.1182\/blood-2013-10-535021\n                      \n                    .","journal-title":"Blood"},{"issue":"4","key":"555_CR19","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.3109\/10428194.2014.946027","volume":"56","author":"GW Lee","year":"2015","unstructured":"Lee GW, Go SI, Kim SH, Hong J, Kim YR, Oh S, et al. Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma. Leuk Lymphoma. 2015;56(4):1020\u20136. \n                      https:\/\/doi.org\/10.3109\/10428194.2014.946027\n                      \n                    .","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"555_CR20","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/his.13106","volume":"70","author":"J Carreras","year":"2017","unstructured":"Carreras J, Kikuti YY, Bea S, Miyaoka M, Hiraiwa S, Ikoma H, et al. Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS). Histopathology. 2017;70(4):595\u2013621. \n                      https:\/\/doi.org\/10.1111\/his.13106.","journal-title":"Histopathology"},{"issue":"2","key":"555_CR21","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/j.1365-2141.2011.08606.x","volume":"153","author":"N Watanabe","year":"2011","unstructured":"Watanabe N, Noh JY, Narimatsu H, Takeuchi K, Yamaguchi T, Kameyama K, et al. Clinicopathological features of 171 cases of primary thyroid lymphoma: a long-term study involving 24553 patients with Hashimoto\u2019s disease. Br J Haematol. 2011;153(2):236\u201343. \n                      https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08606.x\n                      \n                    .","journal-title":"Br J Haematol"},{"issue":"2","key":"555_CR22","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1210\/jc.2014-3250","volume":"100","author":"J Knief","year":"2015","unstructured":"Knief J, Gebauer N, Bernard V, Schemme J, Reddemann K, Gebauer J, et al. Oncogenic mutations and chromosomal aberrations in primary extranodal diffuse large B-cell lymphomas of the thyroid\u2014a study of 21 cases. J Clin Endocrinol Metab. 2015;100(2):754\u201362. \n                      https:\/\/doi.org\/10.1210\/jc.2014-3250\n                      \n                    .","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"555_CR23","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/bjh.14951","volume":"179","author":"L Giulino-Roth","year":"2017","unstructured":"Giulino-Roth L, O'Donohue T, Chen Z, Bartlett NL, LaCasce A, Martin-Doyle W, et al. Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R. Br J Haematol. 2017;179(5):739\u201347. \n                      https:\/\/doi.org\/10.1111\/bjh.14951\n                      \n                    .","journal-title":"Br J Haematol"},{"issue":"9","key":"555_CR24","doi-asserted-by":"publisher","first-page":"e477","DOI":"10.1038\/bcj.2016.88","volume":"6","author":"A Kawajiri","year":"2016","unstructured":"Kawajiri A, Maruyama D, Maeshima AM, Nomoto J, Makita S, Kitahara H, et al. Impact of the double expression of MYC and BCL2 on outcomes of localized primary gastric diffuse large B-cell lymphoma patients in the rituximab era. Blood Cancer J. 2016;6(9):e477. \n                      https:\/\/doi.org\/10.1038\/bcj.2016.88\n                      \n                    .","journal-title":"Blood Cancer J"},{"issue":"11","key":"555_CR25","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1007\/s00277-012-1512-4","volume":"91","author":"BS Sohn","year":"2012","unstructured":"Sohn BS, Kim SM, Yoon DH, Kim S, Lee DH, Kim JH, et al. The comparison between CHOP and R-CHOP in primary gastric diffuse large B cell lymphoma. Ann Hematol. 2012;91(11):1731\u20139. \n                      https:\/\/doi.org\/10.1007\/s00277-012-1512-4\n                      \n                    .","journal-title":"Ann Hematol"},{"key":"555_CR26","doi-asserted-by":"publisher","first-page":"e220","DOI":"10.1038\/bcj.2014.40","volume":"4","author":"SH Kuo","year":"2014","unstructured":"Kuo SH, Yeh KH, Chen LT, Lin CW, Hsu PN, Hsu C, et al. Helicobacter pylori-related diffuse large B-cell lymphoma of the stomach: a distinct entity with lower aggressiveness and higher chemosensitivity. Blood Cancer J. 2014;4:e220. \n                      https:\/\/doi.org\/10.1038\/bcj.2014.40\n                      \n                    .","journal-title":"Blood Cancer J."},{"issue":"5","key":"555_CR27","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1080\/10428194.2017.1370546","volume":"59","author":"M Frick","year":"2018","unstructured":"Frick M, Bettstetter M, Bertz S, Schwarz-Furlan S, Hartmann A, Richter T, et al. Mutational frequencies of CD79B and MYD88 vary greatly between primary testicular DLBCL and gastrointestinal DLBCL. Leuk Lymphoma. 2018;59(5):1260\u20133. \n                      https:\/\/doi.org\/10.1080\/10428194.2017.1370546\n                      \n                    .","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"555_CR28","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/pin.12439","volume":"66","author":"K Nagakita","year":"2016","unstructured":"Nagakita K, Takata K, Taniguchi K, Miyata-Takata T, Sato Y, Tari A, et al. Clinicopathological features of 49 primary gastrointestinal diffuse large B-cell lymphoma cases; comparison with location, cell-of-origin, and frequency of MYD88 L265P. Pathol Int. 2016;66(8):444\u201352. \n                      https:\/\/doi.org\/10.1111\/pin.12439\n                      \n                    .","journal-title":"Pathol Int"},{"issue":"7","key":"555_CR29","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.3324\/haematol.2011.041277","volume":"96","author":"D Villa","year":"2011","unstructured":"Villa D, Connors JM, Sehn LH, Gascoyne RD, Savage KJ. Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapse. Haematologica. 2011;96(7):1002\u20137. \n                      https:\/\/doi.org\/10.3324\/haematol.2011.041277\n                      \n                    .","journal-title":"Haematologica"},{"issue":"11","key":"555_CR30","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.3109\/10428194.2016.1157869","volume":"57","author":"N Lehners","year":"2016","unstructured":"Lehners N, Kramer I, Schwarzbich MA, Ho AD, Witzens-Harig M. Analysis of clinical characteristics and outcome of patients with previously untreated diffuse large B-cell lymphoma and renal involvement in the rituximab era. Leuk Lymphoma. 2016;57(11):2619\u201325. \n                      https:\/\/doi.org\/10.3109\/10428194.2016.1157869\n                      \n                    .","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"555_CR31","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/bjh.14392","volume":"176","author":"R Kridel","year":"2017","unstructured":"Kridel R, Telio D, Villa D, Sehn LH, Gerrie AS, Shenkier T, et al. Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era. Br J Haematol. 2017;176(2):210\u201321. \n                      https:\/\/doi.org\/10.1111\/bjh.14392\n                      \n                    .","journal-title":"Br J Haematol"},{"issue":"2","key":"555_CR32","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/leu.2015.237","volume":"30","author":"L Deng","year":"2016","unstructured":"\u2022 Deng L, Xu-Monette ZY, Loghavi S, Manyam GC, Xia Y, Visco C, et al. Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium. Leukemia. 2016;30(2):361\u201372. \n                      https:\/\/doi.org\/10.1038\/leu.2015.237\n                      \n                    . A multi-institutional observational series describing therapy and outcomes of primary testicular lymphoma. It suggests a benefit of prophylactic intrathecal therapy and radiation therapy, which were associated with lower risk of recurrence.","journal-title":"Leukemia"},{"issue":"3","key":"555_CR33","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/bjh.12753","volume":"165","author":"PJ Hosein","year":"2014","unstructured":"Hosein PJ, Maragulia JC, Salzberg MP, Press OW, Habermann TM, Vose JM, et al. A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era. Br J Haematol. 2014;165(3):358\u201363. \n                      https:\/\/doi.org\/10.1111\/bjh.12753\n                      \n                    .","journal-title":"Br J Haematol"},{"issue":"1","key":"555_CR34","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/ijc.26352","volume":"131","author":"HY Yhim","year":"2012","unstructured":"Yhim HY, Kim JS, Kang HJ, Kim SJ, Kim WS, Choi CW, et al. Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy. Int J Cancer. 2012;131(1):235\u201343. \n                      https:\/\/doi.org\/10.1002\/ijc.26352\n                      \n                    .","journal-title":"Int J Cancer"},{"issue":"2","key":"555_CR35","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/COC.0b013e318209aa12","volume":"35","author":"A Aviles","year":"2012","unstructured":"Aviles A, Neri N, Nambo MJ. The role of genotype in 104 cases of diffuse large B-cell lymphoma primary of breast. Am J Clin Oncol. 2012;35(2):126\u20139. \n                      https:\/\/doi.org\/10.1097\/COC.0b013e318209aa12\n                      \n                    .","journal-title":"Am J Clin Oncol"},{"issue":"11","key":"555_CR36","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1007\/s00277-017-3094-7","volume":"96","author":"XX Cao","year":"2017","unstructured":"Cao XX, Li J, Cai H, Zhang W, Duan MH, Zhou DB. Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of MYD88 and CD79B mutations. Ann Hematol. 2017;96(11):1867\u201371. \n                      https:\/\/doi.org\/10.1007\/s00277-017-3094-7\n                      \n                    .","journal-title":"Ann Hematol"},{"issue":"3","key":"555_CR37","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1097\/PAS.0000000000000592","volume":"40","author":"K Taniguchi","year":"2016","unstructured":"Taniguchi K, Takata K, Chuang SS, Miyata-Takata T, Sato Y, Satou A, et al. Frequent MYD88 L265P and CD79B mutations in primary breast diffuse large B-cell lymphoma. Am J Surg Pathol. 2016;40(3):324\u201334. \n                      https:\/\/doi.org\/10.1097\/PAS.0000000000000592\n                      \n                    .","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"555_CR38","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1111\/bjh.14325","volume":"175","author":"TC El-Galaly","year":"2016","unstructured":"\u2022 El-Galaly TC, Cheah CY, Hutchings M, Mikhaeel NG, Savage KJ, Sehn LH, et al. Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement. Br J Haematol. 2016;175(5):876\u201383. \n                      https:\/\/doi.org\/10.1111\/bjh.14325\n                      \n                    . An intrenational observational study demonstrating high risk of CNS recurrence in DLBCL involving the uterus.","journal-title":"Br J Haematol"},{"issue":"11","key":"555_CR39","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1001\/jamadermatol.2014.821","volume":"150","author":"A Pham-Ledard","year":"2014","unstructured":"Pham-Ledard A, Beylot-Barry M, Barbe C, Leduc M, Petrella T, Vergier B, et al. High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type. JAMA Dermatol. 2014;150(11):1173\u20139. \n                      https:\/\/doi.org\/10.1001\/jamadermatol.2014.821\n                      \n                    .","journal-title":"JAMA Dermatol"},{"issue":"2","key":"555_CR40","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jdermsci.2017.07.008","volume":"88","author":"A Pham-Ledard","year":"2017","unstructured":"Pham-Ledard A, Prochazkova-Carlotti M, Deveza M, Laforet MP, Beylot-Barry M, Vergier B, et al. Molecular analysis of immunoglobulin variable genes supports a germinal center experienced normal counterpart in primary cutaneous diffuse large B-cell lymphoma, leg-type. J Dermatol Sci. 2017;88(2):238\u201346. \n                      https:\/\/doi.org\/10.1016\/j.jdermsci.2017.07.008\n                      \n                    .","journal-title":"J Dermatol Sci"},{"issue":"1","key":"555_CR41","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/bjh.12841","volume":"166","author":"H Wu","year":"2014","unstructured":"Wu H, Zhang L, Shao H, Sokol L, Sotomayor E, Letson D, et al. Prognostic significance of soft tissue extension, international prognostic index, and multifocality in primary bone lymphoma: a single institutional experience. Br J Haematol. 2014;166(1):60\u20138. \n                      https:\/\/doi.org\/10.1111\/bjh.12841\n                      \n                    .","journal-title":"Br J Haematol"},{"issue":"1","key":"555_CR42","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ijrobp.2015.01.014","volume":"92","author":"R Tao","year":"2015","unstructured":"Tao R, Allen PK, Rodriguez A, Shihadeh F, Pinnix CC, Arzu I, et al. Benefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphoma. Int J Radiat Oncol Biol Phys. 2015;92(1):122\u20139. \n                      https:\/\/doi.org\/10.1016\/j.ijrobp.2015.01.014\n                      \n                    .","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"32","key":"555_CR43","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.1200\/JCO.2012.48.0467","volume":"31","author":"G Held","year":"2013","unstructured":"Held G, Zeynalova S, Murawski N, Ziepert M, Kempf B, Viardot A, et al. Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement. J Clin Oncol. 2013;31(32):4115\u201322. \n                      https:\/\/doi.org\/10.1200\/JCO.2012.48.0467\n                      \n                    .","journal-title":"J Clin Oncol"},{"issue":"10","key":"555_CR44","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1097\/PAS.0000000000000923","volume":"41","author":"X Li","year":"2017","unstructured":"Li X, Xu-Monette ZY, Yi S, Dabaja BS, Manyam GC, Westin J, et al. Primary bone lymphoma exhibits a favorable prognosis and distinct gene expression signatures resembling diffuse large B-cell lymphoma derived from centrocytes in the germinal center. Am J Surg Pathol. 2017;41(10):1309\u201321. \n                      https:\/\/doi.org\/10.1097\/PAS.0000000000000923\n                      \n                    .","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"555_CR45","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1080\/10428194.2016.1177180","volume":"57","author":"S Pilorge","year":"2016","unstructured":"Pilorge S, Harel S, Ribrag V, Larousserie F, Willems L, Franchi P, et al. Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies. Leuk Lymphoma. 2016;57(12):2820\u20136. \n                      https:\/\/doi.org\/10.1080\/10428194.2016.1177180\n                      \n                    .","journal-title":"Leuk Lymphoma"},{"issue":"15","key":"555_CR46","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"\u2022 Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378(15):1396\u2013407. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1801445\n                      \n                    . Large translational study identifying DLBCL genotype categories associated with disparate survival outcomes. It identfied the MYD88\/CD79B-mutated genotype particularly prevalent in certain extranodal lymphomas.","journal-title":"N Engl J Med"},{"issue":"28","key":"555_CR47","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","volume":"30","author":"NA Johnson","year":"2012","unstructured":"Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3452\u20139. \n                      https:\/\/doi.org\/10.1200\/JCO.2011.41.0985\n                      \n                    .","journal-title":"J Clin Oncol"},{"issue":"6","key":"555_CR48","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/bjh.12982","volume":"166","author":"Y Oki","year":"2014","unstructured":"Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, et al. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014;166(6):891\u2013901. \n                      https:\/\/doi.org\/10.1111\/bjh.12982\n                      \n                    .","journal-title":"Br J Haematol"},{"issue":"15","key":"555_CR49","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","volume":"124","author":"AM Petrich","year":"2014","unstructured":"Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014;124(15):2354\u201361. \n                      https:\/\/doi.org\/10.1182\/blood-2014-05-578963\n                      \n                    .","journal-title":"Blood"},{"issue":"4","key":"555_CR50","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/leu.2008.344","volume":"23","author":"N Niitsu","year":"2009","unstructured":"Niitsu N, Okamoto M, Miura I, Hirano M. Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24\/c-MYC translocations. Leukemia. 2009;23(4):777\u201383. \n                      https:\/\/doi.org\/10.1038\/leu.2008.344\n                      \n                    .","journal-title":"Leukemia"},{"issue":"17","key":"555_CR51","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1182\/blood-2009-05-220095","volume":"114","author":"KJ Savage","year":"2009","unstructured":"Savage KJ, Johnson NA, Ben-Neriah S, Connors JM, Sehn LH, Farinha P, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009;114(17):3533\u20137. \n                      https:\/\/doi.org\/10.1182\/blood-2009-05-220095\n                      \n                    .","journal-title":"Blood"},{"issue":"7","key":"555_CR52","doi-asserted-by":"publisher","first-page":"935","DOI":"10.3324\/haematol.2008.005355","volume":"94","author":"N Tomita","year":"2009","unstructured":"Tomita N, Tokunaka M, Nakamura N, Takeuchi K, Koike J, Motomura S, et al. Clinicopathological features of lymphoma\/leukemia patients carrying both BCL2 and MYC translocations. Haematologica. 2009;94(7):935\u201343. \n                      https:\/\/doi.org\/10.3324\/haematol.2008.005355\n                      \n                    .","journal-title":"Haematologica"},{"issue":"20","key":"555_CR53","doi-asserted-by":"publisher","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","volume":"121","author":"S Hu","year":"2013","unstructured":"Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, et al. MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013;121(20):4021\u201331; quiz 250. \n                      https:\/\/doi.org\/10.1182\/blood-2012-10-460063\n                      \n                    .","journal-title":"Blood"},{"issue":"18","key":"555_CR54","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1182\/blood-2015-10-676700","volume":"127","author":"KJ Savage","year":"2016","unstructured":"Savage KJ, Slack GW, Mottok A, Sehn LH, Villa D, Kansara R, et al. Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. Blood. 2016;127(18):2182\u20138. \n                      https:\/\/doi.org\/10.1182\/blood-2015-10-676700\n                      \n                    .","journal-title":"Blood"},{"issue":"12","key":"555_CR55","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1182\/blood-2012-06-435842","volume":"121","author":"H Horn","year":"2013","unstructured":"Horn H, Ziepert M, Becher C, Barth TF, Bernd HW, Feller AC, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 2013;121(12):2253\u201363. \n                      https:\/\/doi.org\/10.1182\/blood-2012-06-435842\n                      \n                    .","journal-title":"Blood"},{"issue":"22","key":"555_CR56","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1200\/JCO.2016.70.3660","volume":"35","author":"AM Staiger","year":"2017","unstructured":"Staiger AM, Ziepert M, Horn H, Scott DW, Barth TFE, Bernd HW, et al. Clinical impact of the cell-of-origin classification and the MYC\/ BCL2 dual expresser status in diffuse large B-cell lymphoma treated within prospective clinical trials of the German High-Grade Non-Hodgkin\u2019s Lymphoma Study Group. J Clin Oncol. 2017;35(22):2515\u201326. \n                      https:\/\/doi.org\/10.1200\/JCO.2016.70.3660\n                      \n                    .","journal-title":"J Clin Oncol"},{"issue":"28","key":"555_CR57","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","volume":"30","author":"TM Green","year":"2012","unstructured":"Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3460\u20137. \n                      https:\/\/doi.org\/10.1200\/JCO.2011.41.4342\n                      \n                    .","journal-title":"J Clin Oncol"},{"issue":"19","key":"555_CR58","doi-asserted-by":"publisher","first-page":"3986","DOI":"10.1182\/blood-2012-05-433334","volume":"120","author":"ZY Xu-Monette","year":"2012","unstructured":"Xu-Monette ZY, Wu L, Visco C, Tai YC, Tzankov A, Liu WM, et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2012;120(19):3986\u201396. \n                      https:\/\/doi.org\/10.1182\/blood-2012-05-433334\n                      \n                    .","journal-title":"Blood"},{"issue":"2","key":"555_CR59","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/modpathol.2016.178","volume":"30","author":"XJ Wang","year":"2017","unstructured":"Wang XJ, Medeiros LJ, Bueso-Ramos CE, Tang G, Wang S, Oki Y, et al. P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC\/BCL2 expression in diffuse large B-cell lymphoma. Mod Pathol. 2017;30(2):194\u2013203. \n                      https:\/\/doi.org\/10.1038\/modpathol.2016.178\n                      \n                    .","journal-title":"Mod Pathol"},{"issue":"3","key":"555_CR60","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/leu.2017.251","volume":"32","author":"K Karube","year":"2018","unstructured":"Karube K, Enjuanes A, Dlouhy I, Jares P, Martin-Garcia D, Nadeu F, et al. Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets. Leukemia. 2018;32(3):675\u201384. \n                      https:\/\/doi.org\/10.1038\/leu.2017.251\n                      \n                    .","journal-title":"Leukemia"},{"issue":"2","key":"555_CR61","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","volume":"171","author":"A Reddy","year":"2017","unstructured":"Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell. 2017;171(2):481\u201394 e15. \n                      https:\/\/doi.org\/10.1016\/j.cell.2017.09.027\n                      \n                    .","journal-title":"Cell"},{"issue":"17","key":"555_CR62","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1182\/blood-2008-10-182253","volume":"113","author":"V Boehme","year":"2009","unstructured":"Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood. 2009;113(17):3896\u2013902. \n                      https:\/\/doi.org\/10.1182\/blood-2008-10-182253\n                      \n                    .","journal-title":"Blood"},{"issue":"10","key":"555_CR63","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1093\/annonc\/mdx353","volume":"28","author":"M Gleeson","year":"2017","unstructured":"\u2022 Gleeson M, Counsell N, Cunningham D, Chadwick N, Lawrie A, Hawkes EA, et al. Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial. Ann Oncol. 2017;28(10):2511\u20136. \n                      https:\/\/doi.org\/10.1093\/annonc\/mdx353\n                      \n                    . Re-analysis of a randomized trial, identifying risk factors for CNS recurrence and its association with certain extranodal sites of involvement. It also confirms that parenchymal brain recurrences predominate in the RCHOP era.","journal-title":"Ann Oncol"},{"key":"555_CR64","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ejca.2016.12.029","volume":"75","author":"TC El-Galaly","year":"2017","unstructured":"El-Galaly TC, Villa D, Michaelsen TY, Hutchings M, Mikhaeel NG, Savage KJ, et al. The number of extranodal sites assessed by PET\/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: an international multicenter study of 1532 patients treated with chemoimmunotherapy. Eur J Cancer. 2017;75:195\u2013203. \n                      https:\/\/doi.org\/10.1016\/j.ejca.2016.12.029\n                      \n                    .","journal-title":"Eur J Cancer"},{"issue":"4","key":"555_CR65","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1182\/blood.V91.4.1178","volume":"91","author":"K van Besien","year":"1998","unstructured":"van Besien K, Ha CS, Murphy S, McLaughlin P, Rodriguez A, Amin K, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood. 1998;91(4):1178\u201384.","journal-title":"Blood"},{"issue":"2","key":"555_CR66","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1023\/A:1008260120532","volume":"9","author":"GM Bos","year":"1998","unstructured":"Bos GM, van Putten WL, van der Holt B, van den Bent M, Verdonck LF, Hagenbeek A. For which patients with aggressive non-Hodgkin\u2019s lymphoma is prophylaxis for central nervous system disease mandatory? Dutch HOVON Group. Ann Oncol. 1998;9(2):191\u20134.","journal-title":"Ann Oncol"},{"issue":"7","key":"555_CR67","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1093\/annonc\/mdf175","volume":"13","author":"A Hollender","year":"2002","unstructured":"Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H. Central nervous system involvement following diagnosis of non-Hodgkin\u2019s lymphoma: a risk model. Ann Oncol. 2002;13(7):1099\u2013107.","journal-title":"Ann Oncol"},{"issue":"26","key":"555_CR68","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1200\/JCO.2015.65.6520","volume":"34","author":"N Schmitz","year":"2016","unstructured":"\u2022\u2022 Schmitz N, Zeynalova S, Nickelsen M, Kansara R, Villa D, Sehn LH, et al. CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2016;34(26):3150\u20136. \n                      https:\/\/doi.org\/10.1200\/JCO.2015.65.6520\n                      \n                    . Large observational study describing development of the CNS-IPI in a cohort of clinical trial participants. The index was then validated in an independent population-based cohort from BCCA.","journal-title":"J Clin Oncol"},{"issue":"3","key":"555_CR69","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/bjh.14229","volume":"179","author":"R Kansara","year":"2017","unstructured":"Kansara R, Villa D, Gerrie AS, Klasa R, Shenkier T, Scott DW, et al. Site of central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) by the CNS-IPI risk model. Br J Haematol. 2017;179(3):508\u201310. \n                      https:\/\/doi.org\/10.1111\/bjh.14229\n                      \n                    .","journal-title":"Br J Haematol"},{"issue":"7","key":"555_CR70","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1182\/blood-2017-03-737460","volume":"130","author":"CK Chin","year":"2017","unstructured":"Chin CK, Cheah CY. How I treat patients with aggressive lymphoma at high risk of CNS relapse. Blood. 2017;130(7):867\u201374. \n                      https:\/\/doi.org\/10.1182\/blood-2017-03-737460\n                      \n                    .","journal-title":"Blood"},{"issue":"2","key":"555_CR71","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/bjh.12509.","volume":"163","author":"A McMillan","year":"2013","unstructured":"McMillan A, Ardeshna KM, Cwynarski K, Lyttelton M, McKay P, Montoto S, et al. Guideline on the prevention of secondary central nervous system lymphoma: British Committee for Standards in Haematology. Br J Haematol. 2013;163(2):168\u201381. \n                      https:\/\/doi.org\/10.1111\/bjh.12509.","journal-title":"Br J Haematol"},{"issue":"2","key":"555_CR72","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3324\/haematol.2016.149120","volume":"102","author":"FJ Penalver","year":"2017","unstructured":"Penalver FJ, Sancho JM, de la Fuente A, Olave MT, Martin A, Panizo C, et al. Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO). Haematologica. 2017;102(2):235\u201345. \n                      https:\/\/doi.org\/10.3324\/haematol.2016.149120\n                      \n                    .","journal-title":"Haematologica"},{"issue":"11","key":"555_CR73","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1002\/ajh.24864","volume":"92","author":"MK Malecek","year":"2017","unstructured":"Malecek MK, Petrich AM, Rozell S, Chu B, Trifilio S, Galanina N, et al. Frequency, risk factors, and outcomes of central nervous system relapse in lymphoma patients treated with dose-adjusted EPOCH plus rituximab. Am J Hematol. 2017;92(11):1156\u201362. \n                      https:\/\/doi.org\/10.1002\/ajh.24864\n                      \n                    .","journal-title":"Am J Hematol"},{"issue":"4","key":"555_CR74","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/ejh.12847","volume":"98","author":"B Thakral","year":"2017","unstructured":"Thakral B, Medeiros LJ, Desai P, Lin P, Yin CC, Tang G, et al. Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH. Eur J Haematol. 2017;98(4):415\u201321. \n                      https:\/\/doi.org\/10.1111\/ejh.12847\n                      \n                    .","journal-title":"Eur J Haematol"},{"issue":"4","key":"555_CR75","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/ajh.24299","volume":"91","author":"L Alinari","year":"2016","unstructured":"Alinari L, Gru A, Quinion C, Huang Y, Lozanski A, Lozanski G, et al. De novo CD5+ diffuse large B-cell lymphoma: adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort. Am J Hematol. 2016;91(4):395\u20139. \n                      https:\/\/doi.org\/10.1002\/ajh.24299\n                      \n                    .","journal-title":"Am J Hematol"},{"issue":"8","key":"555_CR76","doi-asserted-by":"publisher","first-page":"5615","DOI":"10.18632\/oncotarget.3479","volume":"6","author":"ZY Xu-Monette","year":"2015","unstructured":"Xu-Monette ZY, Tu M, Jabbar KJ, Cao X, Tzankov A, Visco C, et al. Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in western countries. Oncotarget. 2015;6(8):5615\u201333. \n                      https:\/\/doi.org\/10.18632\/oncotarget.3479.","journal-title":"Oncotarget"},{"issue":"7","key":"555_CR77","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1093\/annonc\/mdq627","volume":"22","author":"K Miyazaki","year":"2011","unstructured":"Miyazaki K, Yamaguchi M, Suzuki R, Kobayashi Y, Maeshima AM, Niitsu N, et al. CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab. Ann Oncol. 2011;22(7):1601\u20137. \n                      https:\/\/doi.org\/10.1093\/annonc\/mdq627\n                      \n                    .","journal-title":"Ann Oncol"},{"issue":"1","key":"555_CR78","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1182\/blood-2005-03-1024","volume":"107","author":"S Camilleri-Broet","year":"2006","unstructured":"Camilleri-Broet S, Criniere E, Broet P, Delwail V, Mokhtari K, Moreau A, et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood. 2006;107(1):190\u20136. \n                      https:\/\/doi.org\/10.1182\/blood-2005-03-1024\n                      \n                    .","journal-title":"Blood"},{"issue":"19","key":"555_CR79","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.1158\/1078-0432.CCR-12-0845","volume":"18","author":"A Gonzalez-Aguilar","year":"2012","unstructured":"Gonzalez-Aguilar A, Idbaih A, Boisselier B, Habbita N, Rossetto M, Laurenge A, et al. Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res. 2012;18(19):5203\u201311. \n                      https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0845\n                      \n                    .","journal-title":"Clin Cancer Res"},{"issue":"7","key":"555_CR80","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","volume":"127","author":"B Chapuy","year":"2016","unstructured":"\u2022\u2022 Chapuy B, Roemer MG, Stewart C, Tan Y, Abo RP, Zhang L, et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016;127(7):869\u201381. \n                      https:\/\/doi.org\/10.1182\/blood-2015-10-673236\n                      \n                    . Translational study identifying common genomic features of primary CNS and testicular lymphoma. These features include prevalent MYD88 and CD79B mutations, as well as copy number alterations involving the PD-L1 \/ PD-L2 genes.","journal-title":"Blood"},{"issue":"17","key":"555_CR81","doi-asserted-by":"publisher","first-page":"3986","DOI":"10.1158\/1078-0432.CCR-14-2116","volume":"21","author":"E Braggio","year":"2015","unstructured":"Braggio E, Van Wier S, Ojha J, McPhail E, Asmann YW, Egan J, et al. Genome-wide analysis uncovers novel recurrent alterations in primary central nervous system lymphomas. Clin Cancer Res. 2015;21(17):3986\u201394. \n                      https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2116\n                      \n                    .","journal-title":"Clin Cancer Res"},{"issue":"19","key":"555_CR82","doi-asserted-by":"publisher","first-page":"5968","DOI":"10.1158\/1078-0432.CCR-09-0108","volume":"15","author":"L Fischer","year":"2009","unstructured":"Fischer L, Korfel A, Pfeiffer S, Kiewe P, Volk HD, Cakiroglu H, et al. CXCL13 and CXCL12 in central nervous system lymphoma patients. Clin Cancer Res. 2009;15(19):5968\u201373. \n                      https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0108\n                      \n                    .","journal-title":"Clin Cancer Res"},{"issue":"8","key":"555_CR83","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/carcin\/bgx061","volume":"38","author":"SA Lemma","year":"2017","unstructured":"Lemma SA, Kuusisto M, Haapasaari KM, Sormunen R, Lehtinen T, Klaavuniemi T, et al. Integrin alpha 10, CD44, PTEN, cadherin-11 and lactoferrin expressions are potential biomarkers for selecting patients in need of central nervous system prophylaxis in diffuse large B-cell lymphoma. Carcinogenesis. 2017;38(8):812\u201320. \n                      https:\/\/doi.org\/10.1093\/carcin\/bgx061\n                      \n                    .","journal-title":"Carcinogenesis"},{"issue":"5","key":"555_CR84","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/ejh.12626","volume":"96","author":"SA Lemma","year":"2016","unstructured":"Lemma SA, Pasanen AK, Haapasaari KM, Sippola A, Sormunen R, Soini Y, et al. Similar chemokine receptor profiles in lymphomas with central nervous system involvement\u2014possible biomarkers for patient selection for central nervous system prophylaxis, a retrospective study. Eur J Haematol. 2016;96(5):492\u2013501. \n                      https:\/\/doi.org\/10.1111\/ejh.12626\n                      \n                    .","journal-title":"Eur J Haematol"},{"issue":"1","key":"555_CR85","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1200\/JCO.2008.16.8021","volume":"27","author":"SH Bernstein","year":"2009","unstructured":"Bernstein SH, Unger JM, Leblanc M, Friedberg J, Miller TP, Fisher RI. Natural history of CNS relapse in patients with aggressive non-Hodgkin\u2019s lymphoma: a 20-year follow-up analysis of SWOG 8516\u2014the Southwest Oncology Group. J Clin Oncol. 2009;27(1):114\u20139. \n                      https:\/\/doi.org\/10.1200\/JCO.2008.16.8021\n                      \n                    .","journal-title":"J Clin Oncol"},{"issue":"11","key":"555_CR86","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1002\/cncr.26588","volume":"118","author":"A Kumar","year":"2012","unstructured":"Kumar A, Vanderplas A, LaCasce AS, Rodriguez MA, Crosby AL, Lepisto E, et al. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. Cancer. 2012;118(11):2944\u201351. \n                      https:\/\/doi.org\/10.1002\/cncr.26588\n                      \n                    .","journal-title":"Cancer"},{"issue":"3","key":"555_CR87","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3109\/10428194.2013.811239","volume":"55","author":"J Zhang","year":"2014","unstructured":"Zhang J, Chen B, Xu X. Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis. Leuk Lymphoma. 2014;55(3):509\u201314. \n                      https:\/\/doi.org\/10.3109\/10428194.2013.811239\n                      \n                    .","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"555_CR88","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/ejh.12763","volume":"97","author":"MF Zahid","year":"2016","unstructured":"Zahid MF, Khan N, Hashmi SK, Kizilbash SH, Barta SK. Central nervous system prophylaxis in diffuse large B-cell lymphoma. Eur J Haematol. 2016;97(2):108\u201320. \n                      https:\/\/doi.org\/10.1111\/ejh.12763\n                      \n                    .","journal-title":"Eur J Haematol"},{"issue":"18","key":"555_CR89","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1002\/cncr.25278","volume":"116","author":"JS Abramson","year":"2010","unstructured":"Abramson JS, Hellmann M, Barnes JA, Hammerman P, Toomey C, Takvorian T, et al. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer. 2010;116(18):4283\u201390. \n                      https:\/\/doi.org\/10.1002\/cncr.25278\n                      \n                    .","journal-title":"Cancer"},{"issue":"5","key":"555_CR90","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/bjh.13194","volume":"168","author":"AJ Ferreri","year":"2015","unstructured":"Ferreri AJ, Bruno-Ventre M, Donadoni G, Ponzoni M, Citterio G, Foppoli M, et al. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era. Br J Haematol. 2015;168(5):654\u201362. \n                      https:\/\/doi.org\/10.1111\/bjh.13194\n                      \n                    .","journal-title":"Br J Haematol"},{"issue":"5","key":"555_CR91","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1093\/annonc\/mds621","volume":"24","author":"H Holte","year":"2013","unstructured":"Holte H, Leppa S, Bjorkholm M, Fluge O, Jyrkkio S, Delabie J, et al. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell\/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Ann Oncol. 2013;24(5):1385\u201392. \n                      https:\/\/doi.org\/10.1093\/annonc\/mds621\n                      \n                    .","journal-title":"Ann Oncol"},{"issue":"9806","key":"555_CR92","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1016\/S0140-6736(11)61040-4","volume":"378","author":"C Recher","year":"2011","unstructured":"Recher C, Coiffier B, Haioun C, Molina TJ, Ferme C, Casasnovas O, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet. 2011;378(9806):1858\u201367. \n                      https:\/\/doi.org\/10.1016\/S0140-6736(11)61040-4\n                      \n                    .","journal-title":"Lancet"},{"issue":"12","key":"555_CR93","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1080\/17402520500182345","volume":"46","author":"JJ Laskin","year":"2005","unstructured":"Laskin JJ, Savage KJ, Voss N, Gascoyne RD, Connors JM. Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemoprophylaxis. Leuk Lymphoma. 2005;46(12):1721\u20137. \n                      https:\/\/doi.org\/10.1080\/17402520500182345\n                      \n                    .","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"555_CR94","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1046\/j.1365-2141.2003.04749.x","volume":"124","author":"MB Moller","year":"2004","unstructured":"Moller MB, Pedersen NT, Christensen BE. Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation\u2014a population-based study of 1575 cases. Br J Haematol. 2004;124(2):151\u20139. \n                      https:\/\/doi.org\/10.1046\/j.1365-2141.2003.04749.x\n                      \n                    .","journal-title":"Br J Haematol"},{"issue":"12","key":"555_CR95","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1080\/10428194.2017.1312381","volume":"58","author":"JC Ho","year":"2017","unstructured":"Ho JC, Dabaja BS, Milgrom SA, Smith GL, Reddy JP, Mazloom A, et al. Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma. Leuk Lymphoma. 2017;58(12):2833\u201344. \n                      https:\/\/doi.org\/10.1080\/10428194.2017.1312381.","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"555_CR96","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1093\/annonc\/mds150","volume":"23","author":"L de Leval","year":"2012","unstructured":"de Leval L, Bonnet C, Copie-Bergman C, Seidel L, Baia M, Briere J, et al. Diffuse large B-cell lymphoma of Waldeyer\u2019s ring has distinct clinicopathologic features: a GELA study. Ann Oncol. 2012;23(12):3143\u201351. \n                      https:\/\/doi.org\/10.1093\/annonc\/mds150\n                      \n                    .","journal-title":"Ann Oncol"},{"issue":"8","key":"555_CR97","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1210\/jc.2013-1428","volume":"98","author":"SA Stein","year":"2013","unstructured":"Stein SA, Wartofsky L. Primary thyroid lymphoma: a clinical review. J Clin Endocrinol Metab. 2013;98(8):3131\u20138. \n                      https:\/\/doi.org\/10.1210\/jc.2013-1428\n                      \n                    .","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"555_CR98","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1093\/annonc\/mdq310","volume":"22","author":"C Onal","year":"2011","unstructured":"Onal C, Li YX, Miller RC, Poortmans P, Constantinou N, Weber DC, et al. Treatment results and prognostic factors in primary thyroid lymphoma patients: a rare cancer network study. Ann Oncol. 2011;22(1):156\u201364. \n                      https:\/\/doi.org\/10.1093\/annonc\/mdq310\n                      \n                    .","journal-title":"Ann Oncol"},{"issue":"4","key":"555_CR99","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/MCP.0000000000000180","volume":"21","author":"J Cardenas-Garcia","year":"2015","unstructured":"Cardenas-Garcia J, Talwar A, Shah R, Fein A. Update in primary pulmonary lymphomas. Curr Opin Pulm Med. 2015;21(4):333\u20137. \n                      https:\/\/doi.org\/10.1097\/MCP.0000000000000180\n                      \n                    .","journal-title":"Curr Opin Pulm Med"},{"issue":"10","key":"555_CR100","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1182\/blood-2011-05-326538","volume":"118","author":"C Steidl","year":"2011","unstructured":"Steidl C, Gascoyne RD. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood. 2011;118(10):2659\u201369. \n                      https:\/\/doi.org\/10.1182\/blood-2011-05-326538\n                      \n                    .","journal-title":"Blood"},{"issue":"15","key":"555_CR101","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1214561","volume":"368","author":"K Dunleavy","year":"2013","unstructured":"Dunleavy K, Pittaluga S, Maeda LS, Advani R, Chen CC, Hessler J, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;368(15):1408\u201316. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1214561\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"4","key":"555_CR102","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/bjh.15051","volume":"180","author":"NN Shah","year":"2018","unstructured":"Shah NN, Szabo A, Huntington SF, Epperla N, Reddy N, Ganguly S, et al. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. Br J Haematol. 2018;180(4):534\u201344. \n                      https:\/\/doi.org\/10.1111\/bjh.15051\n                      \n                    .","journal-title":"Br J Haematol"},{"issue":"21","key":"555_CR103","doi-asserted-by":"publisher","first-page":"4838","DOI":"10.1182\/blood-2012-01-404194","volume":"119","author":"SH Kuo","year":"2012","unstructured":"Kuo SH, Yeh KH, Wu MS, Lin CW, Hsu PN, Wang HP, et al. Helicobacter pylori eradication therapy is effective in the treatment of early-stage H pylori-positive gastric diffuse large B-cell lymphomas. Blood. 2012;119(21):4838\u201344; quiz 5057. \n                      https:\/\/doi.org\/10.1182\/blood-2012-01-404194\n                      \n                    .","journal-title":"Blood"},{"issue":"18","key":"555_CR104","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.1182\/blood-2012-06-438424","volume":"120","author":"AJ Ferreri","year":"2012","unstructured":"Ferreri AJ, Govi S, Raderer M, Mule A, Andriani A, Caracciolo D, et al. Helicobacter pylori eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trial. Blood. 2012;120(18):3858\u201360. \n                      https:\/\/doi.org\/10.1182\/blood-2012-06-438424\n                      \n                    .","journal-title":"Blood"},{"key":"555_CR105","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.humpath.2017.04.011","volume":"64","author":"Y Liu","year":"2017","unstructured":"Liu Y, Yu K, Li M, Zeng K, Wei J, Li X, et al. EZH2 overexpression in primary gastrointestinal diffuse large B-cell lymphoma and its association with the clinicopathological features. Hum Pathol. 2017;64:213\u201321. \n                      https:\/\/doi.org\/10.1016\/j.humpath.2017.04.011\n                      \n                    .","journal-title":"Hum Pathol"},{"issue":"4","key":"555_CR106","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1053\/jhep.2003.50121","volume":"37","author":"JP Bronowicki","year":"2003","unstructured":"Bronowicki JP, Bineau C, Feugier P, Hermine O, Brousse N, Oberti F, et al. Primary lymphoma of the liver: clinical-pathological features and relationship with HCV infection in French patients. Hepatology. 2003;37(4):781\u20137. \n                      https:\/\/doi.org\/10.1053\/jhep.2003.50121\n                      \n                    .","journal-title":"Hepatology"},{"issue":"2","key":"555_CR107","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.yexmp.2016.02.001","volume":"100","author":"Y Peng","year":"2016","unstructured":"Peng Y, Qing AC, Cai J, Yue C, French SW, Qing X. Lymphoma of the liver: clinicopathological features of 19 patients. Exp Mol Pathol. 2016;100(2):276\u201380. \n                      https:\/\/doi.org\/10.1016\/j.yexmp.2016.02.001\n                      \n                    .","journal-title":"Exp Mol Pathol"},{"issue":"8","key":"555_CR108","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1002\/1097-0142(20011015)92:8<2023::AID-CNCR1540>3.0.CO;2-B","volume":"92","author":"RD Page","year":"2001","unstructured":"Page RD, Romaguera JE, Osborne B, Medeiros LJ, Rodriguez J, North L, et al. Primary hepatic lymphoma: favorable outcome after combination chemotherapy. Cancer. 2001;92(8):2023\u20139.","journal-title":"Cancer"},{"issue":"12","key":"555_CR109","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1007\/s00277-013-1812-3","volume":"92","author":"A Rashidi","year":"2013","unstructured":"Rashidi A, Fisher SI. Primary adrenal lymphoma: a systematic review. Ann Hematol. 2013;92(12):1583\u201393. \n                      https:\/\/doi.org\/10.1007\/s00277-013-1812-3\n                      \n                    .","journal-title":"Ann Hematol"},{"key":"555_CR110","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1756-8722-5-49","volume":"5","author":"YR Kim","year":"2012","unstructured":"Kim YR, Kim JS, Min YH, Hyunyoon D, Shin HJ, Mun YC, et al. Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL). J Hematol Oncol. 2012;5:49. \n                      https:\/\/doi.org\/10.1186\/1756-8722-5-49\n                      \n                    .","journal-title":"J Hematol Oncol"},{"key":"555_CR111","doi-asserted-by":"publisher","unstructured":"Hussain S, Hallam S, Beltran L, Haroon A, Majumdar K, Shamash J, et al. Intravascular large B-cell lymphoma presenting as a pituitary mass with bilateral adrenal enlargement and haemophagocytic lymphohistiocytosis. Br J Haematol. 2017; \n                      https:\/\/doi.org\/10.1111\/bjh.14715\n                      \n                    .","DOI":"10.1111\/bjh.14715"},{"key":"555_CR112","doi-asserted-by":"publisher","unstructured":"Schrader AMR, Jansen PM, Willemze R, Vermeer MH, Cleton-Jansen AM, Somers SF, et al. High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma. Blood. 2018; \n                      https:\/\/doi.org\/10.1182\/blood-2017-12-822817\n                      \n                    .","DOI":"10.1182\/blood-2017-12-822817"},{"issue":"3","key":"555_CR113","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/leu.2013.348","volume":"28","author":"W Kraan","year":"2014","unstructured":"Kraan W, van Keimpema M, Horlings HM, Schilder-Tol EJ, Oud ME, Noorduyn LA, et al. High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma. Leukemia. 2014;28(3):719\u201320. \n                      https:\/\/doi.org\/10.1038\/leu.2013.348\n                      \n                    .","journal-title":"Leukemia"},{"issue":"10","key":"555_CR114","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/pin.12336","volume":"65","author":"N Oishi","year":"2015","unstructured":"Oishi N, Kondo T, Nakazawa T, Mochizuki K, Tanioka F, Oyama T, et al. High prevalence of the MYD88 mutation in testicular lymphoma: immunohistochemical and genetic analyses. Pathol Int. 2015;65(10):528\u201335. \n                      https:\/\/doi.org\/10.1111\/pin.12336\n                      \n                    .","journal-title":"Pathol Int"},{"issue":"20","key":"555_CR115","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1200\/JCO.2010.31.4187","volume":"29","author":"U Vitolo","year":"2011","unstructured":"Vitolo U, Chiappella A, Ferreri AJ, Martelli M, Baldi I, Balzarotti M, et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol. 2011;29(20):2766\u201372. \n                      https:\/\/doi.org\/10.1200\/JCO.2010.31.4187\n                      \n                    .","journal-title":"J Clin Oncol"},{"key":"555_CR116","doi-asserted-by":"crossref","unstructured":"Ollila TA, Olszewski AJ. Radiation therapy in primary testicular lymphoma (PTL): does practice match the standard of care? ASCO Annual Meeting. 2018. Abs. 7544.","DOI":"10.1200\/JCO.2018.36.15_suppl.7544"},{"issue":"2","key":"555_CR117","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/annonc\/mdm471","volume":"19","author":"G Ryan","year":"2008","unstructured":"Ryan G, Martinelli G, Kuper-Hommel M, Tsang R, Pruneri G, Yuen K, et al. Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Ann Oncol. 2008;19(2):233\u201341. \n                      https:\/\/doi.org\/10.1093\/annonc\/mdm471\n                      \n                    .","journal-title":"Ann Oncol"},{"key":"555_CR118","doi-asserted-by":"publisher","unstructured":"Thomas A, Link BK, Altekruse S, Romitti PA, Schroeder MC. Primary breast lymphoma in the United States: 1975\u20132013. J Natl Cancer Inst. 2017;109(6) \n                      https:\/\/doi.org\/10.1093\/jnci\/djw294\n                      \n                    .","DOI":"10.1093\/jnci\/djw294"},{"issue":"6","key":"555_CR119","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s00277-013-2003-y","volume":"93","author":"XX Cao","year":"2014","unstructured":"Cao XX, Li J, Zhang W, Duan MH, Shen T, Zhou DB. Patients with primary diffuse large B-cell lymphoma of female genital tract have high risk of central nervous system relapse. Ann Hematol. 2014;93(6):1001\u20135. \n                      https:\/\/doi.org\/10.1007\/s00277-013-2003-y\n                      \n                    .","journal-title":"Ann Hematol"},{"issue":"10","key":"555_CR120","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/ajh.24462","volume":"91","author":"RA Wilcox","year":"2016","unstructured":"Wilcox RA. Cutaneous B-cell lymphomas: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91(10):1052\u20135. \n                      https:\/\/doi.org\/10.1002\/ajh.24462\n                      \n                    .","journal-title":"Am J Hematol"},{"issue":"5","key":"555_CR121","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1001\/jamadermatol.2013.7452","volume":"150","author":"F Grange","year":"2014","unstructured":"Grange F, Joly P, Barbe C, Bagot M, Dalle S, Ingen-Housz-Oro S, et al. Improvement of survival in patients with primary cutaneous diffuse large B-cell lymphoma, leg type, in France. JAMA Dermatol. 2014;150(5):535\u201341. \n                      https:\/\/doi.org\/10.1001\/jamadermatol.2013.7452\n                      \n                    .","journal-title":"JAMA Dermatol"},{"issue":"3","key":"555_CR122","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/modpathol.2013.156","volume":"27","author":"A Pham-Ledard","year":"2014","unstructured":"Pham-Ledard A, Prochazkova-Carlotti M, Andrique L, Cappellen D, Vergier B, Martinez F, et al. Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma. Mod Pathol. 2014;27(3):402\u201311. \n                      https:\/\/doi.org\/10.1038\/modpathol.2013.156\n                      \n                    .","journal-title":"Mod Pathol"},{"issue":"9","key":"555_CR123","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1182\/blood-2004-04-1594","volume":"105","author":"JJ Hoefnagel","year":"2005","unstructured":"Hoefnagel JJ, Dijkman R, Basso K, Jansen PM, Hallermann C, Willemze R, et al. Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood. 2005;105(9):3671\u20138. \n                      https:\/\/doi.org\/10.1182\/blood-2004-04-1594\n                      \n                    .","journal-title":"Blood"},{"issue":"11","key":"555_CR124","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1111\/jdv.14358","volume":"31","author":"E Gardette","year":"2017","unstructured":"Gardette E, Maraval A, Brunet-Possenti F, Quereux G, Beltraminelli H, Templier I, et al. Central nervous system involvement of primary cutaneous diffuse large B-cell lymphoma, leg type: 13 cases. J Eur Acad Dermatol Venereol. 2017;31(11):e498\u2013501. \n                      https:\/\/doi.org\/10.1111\/jdv.14358.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"555_CR125","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/1097-0142(20000815)89:4<913::AID-CNCR26>3.0.CO;2-8","volume":"89","author":"MW Bekkenk","year":"2000","unstructured":"Bekkenk MW, Postma TJ, Meijer CJ, Willemze R. Frequency of central nervous system involvement in primary cutaneous B-cell lymphoma. Cancer. 2000;89(4):913\u20139.","journal-title":"Cancer"},{"issue":"3","key":"555_CR126","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1634\/theoncologist.2013-0249","volume":"19","author":"M Bruno Ventre","year":"2014","unstructured":"Bruno Ventre M, Ferreri AJ, Gospodarowicz M, Govi S, Messina C, Porter D, et al. Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 study). Oncologist. 2014;19(3):291\u20138. \n                      https:\/\/doi.org\/10.1634\/theoncologist.2013-0249\n                      \n                    .","journal-title":"Oncologist"},{"issue":"6","key":"555_CR127","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1111\/bjh.12714","volume":"164","author":"C Messina","year":"2014","unstructured":"Messina C, Ferreri AJ, Govi S, Bruno-Ventre M, Gracia Medina EA, Porter D, et al. Clinical features, management and prognosis of multifocal primary bone lymphoma: a retrospective study of the international extranodal lymphoma study group (the IELSG 14 study). Br J Haematol. 2014;164(6):834\u201340. \n                      https:\/\/doi.org\/10.1111\/bjh.12714\n                      \n                    .","journal-title":"Br J Haematol"},{"issue":"39","key":"555_CR128","doi-asserted-by":"publisher","first-page":"65609","DOI":"10.18632\/oncotarget.19936.","volume":"8","author":"Y Xu","year":"2017","unstructured":"Xu Y, Li J, Ouyang J, Li J, Xu J, Zhang Q, et al. Prognostic relevance of protein expression, clinical factors, and MYD88 mutation in primary bone lymphoma. Oncotarget. 2017;8(39):65609\u201319. \n                      https:\/\/doi.org\/10.18632\/oncotarget.19936.","journal-title":"Oncotarget"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-018-0555-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-018-0555-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-018-0555-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T14:08:14Z","timestamp":1589724494000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-018-0555-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,21]]},"references-count":128,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["555"],"URL":"https:\/\/doi.org\/10.1007\/s11864-018-0555-8","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,21]]},"assertion":[{"value":"21 June 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"38"}}